Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach

被引:148
作者
Richy, F
Bruyere, O
Ethgen, O
Rabenda, V
Bouvenot, G
Audran, M
Herrero-Beaumont, G
Moore, A
Eliakim, R
Haim, M
Reginster, JY
机构
[1] Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium
[2] WHO, Collaborating Ctr Publ Hlth Aspects Osteoarticula, Liege, Belgium
[3] Hop St Marguerite, Ctr Hosp Reg & Univ Marseille, Dept Internal Med & Therapeut, Marseille, France
[4] CHRU Fac Angers, Dept Rheumatol, Angers, France
[5] Dept Rheumatol, Madrid, Spain
[6] The Churchill, Oxford, England
[7] Rambam Med Ctr, Dept Gastroenterol, Haifa, Israel
[8] Merck & Co Inc, Paris, France
关键词
D O I
10.1136/ard.2003.015925
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies. Methods: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study, duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse effects, publication range January 1985 to January 2003. The publications retrieved were assessed during a specifically dedicated WHO meeting including leading experts in all related fields. Statistics were performed conservatively. Meta-regression was performed by regressing NSAID adjusted estimates against study duration categories. Results: Among RCT data, indolic derivates provided a significantly higher risk of GI complications related to NSAID use than for non-users: RR = 2.25 (1.00; 5.08) than did other compounds: naproxen: RR = 1.83 (1.25; 2.68); diclofenac: RR = 1.73 (1.21; 2.46); piroxicam: RR = 1.66 (1.14; 2.44); tenoxicam: RR = 1.43 (0.40; 5.14); meloxicam: RR = 1.24 (0.98; 1.56), and ibuprofen: RR = 1.19 (0.93; 1.54). Indometacin users had a maximum relative risk for complication at 14 days. The other compounds presented a better profile, with a maximum risk at 50 days. Significant additional risk factors included age, dose, and underlying disease. The controlled cohort studies provided higher estimates: RR = 2.22 (1.7; 2.9). Publication bias testing was significant, towards a selective publication of deleterious effects of NSAIDs from small sized studies. Conclusion: This meta-analysis characterised the "compound'' and "time'' aspects of the GI toxicity of non-selective NSAIDs. The risk/benefit ratio of such compounds should thus be carefully and individually evaluated at the start of long term treatment.
引用
收藏
页码:759 / 766
页数:8
相关论文
共 80 条
  • [1] GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    ALLISON, MC
    HOWATSON, AG
    TORRANCE, CJ
    LEE, FD
    RUSSELL, RI
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) : 749 - 754
  • [2] Double-blind, placebo-controlled study on effect of diclofenac sodium and indomethacin on postprandial gastric motility in man
    Bassotti, G
    Bucaneve, G
    Furno, P
    Morelli, A
    Del Favero, A
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (06) : 1172 - 1176
  • [3] NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND HOSPITALIZATION FOR GASTROESOPHAGEAL BLEEDING IN THE ELDERLY
    BEARD, K
    WALKER, AM
    PERERA, DR
    JICK, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (09) : 1621 - 1623
  • [4] BEARDON PHG, 1989, Q J MED, V71, P497
  • [5] A DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED TRIAL OF LORNOXICAM IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND KNEE
    BERRY, H
    BIRD, HA
    BLACK, C
    BLAKE, DR
    FREEMAN, AM
    GOLDING, DN
    HAMILTON, EBD
    JAYSON, MIV
    KIDD, B
    KOHN, H
    MILLION, R
    OLLIER, S
    SMITH, I
    WILLIAMS, BD
    WOOLF, AD
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1992, 51 (02) : 238 - 242
  • [7] THE IMPACT OF RESEARCH QUALITY AND STUDY DESIGN ON EPIDEMIOLOGIC ESTIMATES OF THE EFFECT OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON UPPER GASTROINTESTINAL-TRACT DISEASE
    BOLLINI, P
    RODRIGUEZ, LAG
    GUTTHANN, SP
    WALKER, AM
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (06) : 1289 - 1295
  • [8] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [9] OXAPROZIN IN THE TREATMENT OF PATIENTS WITH TENDINITIS AND BURSITIS - COMPARISON WITH PHENYLBUTAZONE AND PLACEBO
    BONO, RF
    FINKEL, S
    GOODMAN, HF
    HANNA, CB
    RABINOWITZ, SR
    SHARON, E
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 1986, 15 (03) : 90 - 94
  • [10] Burssens A, 1995, Acta Orthop Belg, V61, P205